Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Alimta ANDA Products Hit Double Digits With Several Launches

Fresenius Kabi Has ‘Broadest Portfolio Available’

Executive Summary

Following patent expiry on 24 May, Alimta ANDA products have reached the US market, eating into a product that generated more than $1.2bn in sales last year.

You may also be interested in...



Dr Reddy’s Follows Viatris With Second US Nexavar Rival

Hot on the heels of the first US generic Nexavar launch by Viatris, Dr Reddy’s has followed with a second sorafenib rival. The product represents the latest in a string of significant US launches for the Indian company.

Sandoz Launches Pemetrexed In 11 European Countries

Sandoz has launched its generic pemetrexed rival to Alimta in a ready-to-dilute 1,000mg presentation in 11 EU countries including Germany, Switzerland, the Netherlands and Spain.

Sawai Lines Up Eight Launches In Japan

Sawai is lining up eight launches as part of the Japanese company’s strategy to capture an increased share of its domestic generics market.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

GB151926

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel